Skip to main content
. Author manuscript; available in PMC: 2015 Mar 17.
Published in final edited form as: Diabetes. 2014 Aug 11;64(1):299–310. doi: 10.2337/db14-0104

Figure 2. Predicted consequences of the perilipin-1 439fs mutant and documentation of its expression in adipose tissue.

Figure 2

A) A schematic representation of the expected effects of the perilipin-1 439fs mutation on the protein domain organisation. B) Immunoblots showing perilipin-1 and 2 expression in adipose tissue samples from proband A (these include a visceral fat and subcutaneous leg fat sample) compared with expression in subcutaneous abdominal fat samples from two control samples. The N-terminal perilipin-1 antibody (GP29) detects both mutant (arrow) and wild type perilipin-1, whereas the C-terminal antibody only detects wild type perilipin-1. Calnexin was used as a loading control.

HHS Vulnerability Disclosure